# The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies

> **NCT05487443** · PHASE2,PHASE3 · UNKNOWN · sponsor: **First People's Hospital of Hangzhou** · enrollment: 50 (estimated)

## Conditions studied

- Gemcitabine
- Biliary Tract Cancer
- Immune Checkpoint Inhibitors

## Interventions

- **DRUG:** Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors

## Key facts

- **NCT ID:** NCT05487443
- **Lead sponsor:** First People's Hospital of Hangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05487443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05487443, "The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05487443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*